FR19C1005I2 - Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation - Google Patents

Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation

Info

Publication number
FR19C1005I2
FR19C1005I2 FR19C1005C FR19C1005C FR19C1005I2 FR 19C1005 I2 FR19C1005 I2 FR 19C1005I2 FR 19C1005 C FR19C1005 C FR 19C1005C FR 19C1005 C FR19C1005 C FR 19C1005C FR 19C1005 I2 FR19C1005 I2 FR 19C1005I2
Authority
FR
France
Prior art keywords
nanobody
aggregation
enhanced
treatment
related disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1005C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of FR19C1005I1 publication Critical patent/FR19C1005I1/fr
Application granted granted Critical
Publication of FR19C1005I2 publication Critical patent/FR19C1005I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR19C1005C 2005-05-20 2019-02-13 Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation Active FR19C1005I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68347405P 2005-05-20 2005-05-20
EP06776035A EP2007814A2 (en) 2005-05-20 2006-05-19 Single domain vhh antibodies against von willebrand factor
PCT/EP2006/004773 WO2006122825A2 (en) 2005-05-20 2006-05-19 Single domain vhh antibodies against von willebrand factor

Publications (2)

Publication Number Publication Date
FR19C1005I1 FR19C1005I1 (fr) 2019-03-22
FR19C1005I2 true FR19C1005I2 (fr) 2020-01-31

Family

ID=37431613

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1005C Active FR19C1005I2 (fr) 2005-05-20 2019-02-13 Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation

Country Status (28)

Country Link
US (3) US7807162B2 (enExample)
EP (4) EP2007814A2 (enExample)
JP (1) JP4986997B2 (enExample)
KR (1) KR101414438B1 (enExample)
CN (1) CN101213214B (enExample)
AU (1) AU2006249090B2 (enExample)
BE (1) BE2019C503I2 (enExample)
BR (1) BRPI0609797B8 (enExample)
CA (2) CA2608873C (enExample)
CY (2) CY1122579T1 (enExample)
DK (1) DK2444424T3 (enExample)
ES (2) ES2852423T3 (enExample)
FR (1) FR19C1005I2 (enExample)
HU (2) HUE039846T2 (enExample)
IL (2) IL187168A (enExample)
LT (2) LT2444424T (enExample)
LU (1) LUC00099I2 (enExample)
MX (1) MX2007014564A (enExample)
NL (1) NL300966I2 (enExample)
NO (3) NO20076475L (enExample)
NZ (1) NZ563392A (enExample)
PL (2) PL2444424T3 (enExample)
PT (2) PT2444424T (enExample)
RU (1) RU2433139C2 (enExample)
SI (1) SI2444424T1 (enExample)
TR (1) TR201815552T4 (enExample)
WO (1) WO2006122825A2 (enExample)
ZA (1) ZA200709570B (enExample)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2010081856A1 (en) * 2009-01-14 2010-07-22 Ablynx Nv Pulmonary administration of immunoglobulin single variable domains and constructs thereof
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
EP4353819A3 (en) 2004-07-22 2024-07-17 Erasmus University Medical Center Rotterdam Binding molecules
PL1836500T3 (pl) 2005-01-14 2010-12-31 Ablynx Nv Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
WO2008049881A2 (en) * 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
WO2008049897A1 (en) * 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2012130874A1 (en) * 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
CA2678218A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
AU2008252853B2 (en) * 2007-05-24 2011-12-01 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
US10214588B2 (en) 2007-07-03 2019-02-26 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
CN101970490A (zh) * 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
CN101932593B (zh) * 2008-01-29 2014-08-20 埃博灵克斯股份有限公司 稳定蛋白和多肽的方法
CN101965362A (zh) * 2008-03-05 2011-02-02 埃博灵克斯股份有限公司 新型抗原结合二聚体-复合物及其制备方法和应用
EP2252303A2 (en) * 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
CA2731617A1 (en) 2008-07-22 2010-01-28 Maria Joao Saraiva Amino acid sequences directed against multitarget scavenger receptors and polypeptides
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
AU2010243551B2 (en) 2009-04-30 2015-03-26 Ablynx Nv Method for the production of domain antibodies
DK2451839T3 (da) 2009-07-10 2020-07-13 Ablynx Nv Fremgangsmåde til produktion af variable domæner
PT2473528E (pt) 2009-09-03 2015-03-04 Ablynx NV Formulações estáveis de polipéptidos e seus usos
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
EP2506874A1 (en) 2009-12-01 2012-10-10 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
RS67588B1 (sr) 2009-12-14 2026-01-30 Ablynx Nv Antitela sa pojedinačnim varijabilnim domenom imunoglobulina protiv ox40l, konstrukti i njihova terapijska upotreba
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2533761B1 (en) 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
AP2012006359A0 (en) 2010-03-03 2012-08-31 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ES2996232T3 (en) 2010-10-29 2025-02-12 Ablynx Nv Method for the production of immunoglobulin single variable domains
JP5933573B2 (ja) 2010-11-08 2016-06-15 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
WO2012130872A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
CN108329391A (zh) * 2011-05-27 2018-07-27 埃博灵克斯股份有限公司 使用rankl结合肽抑制骨质吸收
RS55775B2 (sr) 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
PH12022550313A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
AU2012273928A1 (en) 2011-06-23 2014-02-06 Ablynx Nv Immunoglobulin single variable domains directed against IgE
EP4350345A3 (en) 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
PH12014500380A1 (en) * 2011-08-17 2022-05-02 Glaxo Group Ltd Modified proteins and peptides
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
DE102011121238A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
DE102011121237A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
ES2715279T3 (es) 2012-05-24 2019-06-03 Vib Vzw Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores
MX362394B (es) * 2012-06-08 2019-01-15 Glenmark Pharmaceuticals Sa Anticuerpos anti-trka humanizados con sustituciones de aminoacidos.
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CA2899693C (en) 2013-01-30 2023-03-14 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
DK2953973T3 (da) 2013-02-05 2019-08-12 Vib Vzw Muskarine acetylcholinreceptor-bindemidler og anvendelser deraf
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
JP6499090B2 (ja) 2013-03-15 2019-04-10 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 心血管疾患において使用するための抗マクロファージマンノース受容体単一可変ドメイン
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
US20160130361A1 (en) * 2013-06-13 2016-05-12 Biogen Ma Inc. Anti-factor viii antibodies or uses thereof
AU2015217846B2 (en) 2014-01-30 2019-10-10 The Board Of Trustees Of The Leland Stanford Junior University Opioid receptor binding agents and uses thereof
ES2924393T3 (es) * 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos
DK3143403T3 (da) 2014-05-16 2022-01-17 Ablynx Nv Fremgangsmåder til påvisning og/eller måling af anti-lægemiddelantistoffer, især behandlingsinducerede anti-lægemiddelantistoffer
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
PT3194976T (pt) 2014-07-22 2020-07-03 Univ Brussel Vrije Métodos para selecionar agentes que estabilizam complexos proteicos
CA2961774C (en) 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
CA2971278C (en) 2014-12-19 2023-09-19 Ablynx N.V. Cysteine linked nanobody dimers
WO2016156570A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
ES2754427T3 (es) 2015-05-13 2020-04-17 Ablynx Nv Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta
PL3294319T3 (pl) 2015-05-13 2024-10-07 Ablynx Nv Polipeptydy rekrutujące komórki t na podstawie reaktywności cd3
US10639307B2 (en) 2015-05-15 2020-05-05 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
KR102709681B1 (ko) 2015-07-31 2024-09-26 메디뮨 리미티드 헵시딘 매개 장애의 치료 방법
NO2768984T3 (enExample) 2015-11-12 2018-06-09
LT3374392T (lt) 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
WO2017085172A2 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
KR20180083418A (ko) * 2015-11-18 2018-07-20 머크 샤프 앤드 돔 코포레이션 Pd1/ctla4 결합제
AU2016360987A1 (en) 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
US10626186B2 (en) * 2016-01-26 2020-04-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-VWF D'D3 single-domain antibodies and methods of use
CA3022697A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
WO2017197231A1 (en) * 2016-05-13 2017-11-16 Medimmune, Llc Cd40l-fc fusion polypeptides and methods of use thereof
CA3024723A1 (en) 2016-05-20 2017-11-23 Robert B. Dubridge Single domain serum albumin binding protein
PT3461261T (pt) 2016-05-20 2025-07-31 Harpoon Therapeutics Inc Proteínas de ligação ao cd3 de fragmento variável de cadeia única
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109313183B (zh) 2016-06-23 2022-10-21 埃博灵克斯股份有限公司 免疫球蛋白单可变结构域的改进的药代动力学测定
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CA3043515A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
EP3544997A4 (en) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
KR102662499B1 (ko) 2017-01-17 2024-05-02 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
MX2019008536A (es) 2017-01-17 2019-09-10 Ablynx Nv Aglutinantes de albumina serica mejorados.
WO2018144773A1 (en) 2017-02-01 2018-08-09 Yale University Treatment of diuretic resistance
KR102616335B1 (ko) 2017-02-28 2023-12-21 브이아이비 브이지더블유 경구 단백질 전달을 위한 수단 및 방법
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN110546506B (zh) 2017-03-31 2023-04-04 埃博灵克斯股份有限公司 改进的免疫原性测定法
US10865238B1 (en) * 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2018206734A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
CN115028727A (zh) 2017-05-12 2022-09-09 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
BR112019023855B1 (pt) * 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
WO2018220235A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
BR112019024333A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação adamts
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
US11813307B2 (en) 2017-06-02 2023-11-14 Merck Patent Gmbh Polypeptides binding ADAMTS5, MMP13 and aggrecan
CN111108126B (zh) 2017-07-19 2024-04-26 非营利性组织佛兰芒综合大学生物技术研究所 血清白蛋白结合剂
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019086548A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
US20200199206A1 (en) * 2017-12-08 2020-06-25 AC Thera, LLC Bacterial toxin-neutralizing nanobodies and methods of making and using the same
JP7395479B2 (ja) 2018-01-05 2023-12-11 ノヴォ ノルディスク アー／エス 免疫抑制なしにｉｌ－６媒介性炎症を処置する方法
CN112004826B (zh) 2018-02-05 2024-06-14 自由大学基金会 反向激动性抗us28抗体
MY204220A (en) 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
US20200392512A1 (en) 2018-02-26 2020-12-17 Ablynx N.V. Nucleotide sequences encoding peptide linkers
US11858960B2 (en) 2018-03-01 2024-01-02 Vrije Universiteit Brussel Human PD-L1-binding immunoglobulins
CA3095080A1 (en) 2018-03-27 2019-10-03 Coen MAAS Targeted thrombolysis for treatment of microvascular thrombosis
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
US12220459B2 (en) 2019-04-02 2025-02-11 Nykode Therapeutics ASA Immune-stimulatory compositions and use thereof
EP3963329A1 (en) 2019-04-29 2022-03-09 Confo Therapeutics N.V. Screening methods and assays for use with transmembrane proteins, in particular with gpcrs
EP3962599A1 (en) 2019-04-30 2022-03-09 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
MA55809B1 (fr) 2019-05-01 2025-12-31 Novo Nordisk A/S Formulations d'anticorps anti-il-6
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
US12472254B2 (en) 2019-05-28 2025-11-18 Vib Vzw CD8+ T-cells lacking plexins and their application in cancer treatment
EP4010079A1 (en) 2019-08-05 2022-06-15 Stichting VU Identification and elimination of hcmv-infected cells
WO2021039574A1 (ja) * 2019-08-23 2021-03-04 株式会社カネカ Ｏ結合型糖鎖修飾が抑制された重鎖抗体
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
WO2021078786A1 (en) 2019-10-21 2021-04-29 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
BR112022009087A2 (pt) 2019-11-11 2022-07-26 Ibi Ag Innovative Bio Insecticides Ltd Nanocorpos para controle de insetos e usos dos mesmos
CA3158991A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
EP4110794A1 (en) 2020-02-25 2023-01-04 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
WO2021213435A1 (zh) 2020-04-22 2021-10-28 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1(pd-l1)的单可变域抗体及其衍生物
WO2021222546A1 (en) * 2020-05-01 2021-11-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for identifying nanobodies and nanobody affinities
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2021258160A1 (en) * 2020-06-26 2021-12-30 Monash University Anti-vwf antibodies and uses thereof
CA3187283A1 (en) * 2020-06-29 2022-01-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
AR122933A1 (es) 2020-07-10 2022-10-19 Novo Nordisk As Métodos para tratar la enfermedad cardiovascular
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
CA3196737A1 (en) 2020-09-24 2022-03-31 Massimiliano Mazzone Combination of p2y6 inhibitors and immune checkpoint inhibitors
MX2023003522A (es) 2020-09-25 2023-04-19 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022133050A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Gpc3 binding molecules and uses thereof
WO2022133089A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Cea6 binding molecules and uses thereof
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
EP4263612A4 (en) * 2020-12-18 2025-04-02 Bioardis LLC Mesothelin binding molecules and uses thereof
EP4263601A4 (en) * 2020-12-18 2025-04-02 Bioardis LLC Epcam binding molecules and uses thereof
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
US20240084039A1 (en) * 2020-12-23 2024-03-14 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2022136693A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2022136650A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Murine cross-reactive human ccr8 binders
CA3206304A1 (en) 2020-12-24 2022-06-30 Vib Vzw Human ccr8 binders
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
CA3207548A1 (en) 2021-02-05 2022-08-11 Xavier Saelens Sarbecovirus binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
CA3211270A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
US20240369570A1 (en) 2021-04-09 2024-11-07 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2022268993A1 (en) 2021-06-23 2022-12-29 Vib Vzw Means and methods for selection of specific binders
CN117580865A (zh) 2021-06-29 2024-02-20 山东先声生物制药有限公司 Cd16抗体及其应用
US20250336476A1 (en) * 2021-07-12 2025-10-30 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and sytems for nanobody humanization
WO2023006040A1 (zh) 2021-07-30 2023-02-02 江苏先声药业有限公司 抗pvrig/抗tigit双特异性抗体和应用
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
US20240271186A1 (en) 2021-08-03 2024-08-15 Wageningen Universiteit Argonaute-based nucleic acid detection system
EP4428156A4 (en) 2021-12-03 2026-03-04 Shandong Simcere Biopharmaceutical Co., Ltd. ANTI-BCMA NANOBODY AND USE THEREOF
TW202342508A (zh) 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
WO2023125888A1 (zh) 2021-12-31 2023-07-06 山东先声生物制药有限公司 一种gprc5d抗体及其应用
US20250304664A1 (en) 2022-01-12 2025-10-02 Vib Vzw Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
CN119998313A (zh) 2022-05-18 2025-05-13 Vib研究所 沙贝病毒刺突蛋白s2亚基结合剂
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
CA3258254A1 (en) 2022-06-06 2025-04-07 Shandong Simcere Biopharmaceutical Co., Ltd. Multi-specific antibody targeting bcma, gprc5d and t cells and application thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
EP4551600A1 (en) 2022-07-04 2025-05-14 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
KR102749341B1 (ko) 2022-07-08 2025-01-06 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
WO2024013402A1 (en) 2022-07-15 2024-01-18 Gadeta B.V. Novel soluble gamma t-cell (or soluble delta t-cell) receptor chains (or soluble gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
JP2025526384A (ja) 2022-07-27 2025-08-13 アブリンクス エン．ヴェー． 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4620974A1 (en) 2022-11-15 2025-09-24 Oricell Therapeutics Co., Ltd. Anti-afp/hla02 tcr-like antibody and use thereof
EP4619156A1 (en) 2022-11-15 2025-09-24 Imec VZW Method and system for droplet manipulation
WO2024126685A1 (en) * 2022-12-15 2024-06-20 Institut National de la Santé et de la Recherche Médicale Single-domain antibody targeting von wilebrand factor a3-domain
AR131388A1 (es) 2022-12-15 2025-03-12 Univ Aarhus Activación sintética de receptores transmembrana multiméricos
AU2023410327A1 (en) 2022-12-19 2025-06-05 Umc Utrecht Holding B.V. Btn2a1 binding peptide
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
EP4655324A1 (en) 2023-01-27 2025-12-03 Vib Vzw Cd163-binding conjugates
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
EP4662246A1 (en) 2023-02-09 2025-12-17 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
EP4665755A1 (en) 2023-02-17 2025-12-24 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
EP4680624A1 (en) 2023-03-14 2026-01-21 Aarhus Universitet Genetically altered nfr5 receptor kinases
CN121358771A (zh) 2023-04-03 2026-01-16 非营利性组织佛兰芒综合大学生物技术研究所 血-脑屏障穿越抗体
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024251826A1 (en) 2023-06-05 2024-12-12 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251981A1 (en) 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
GB202314424D0 (en) 2023-09-20 2023-11-01 Cambridge Entpr Ltd A conjugate
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025167664A1 (zh) * 2024-02-07 2025-08-14 原启生物科技(上海)有限责任公司 Ror1抗原结合蛋白及其用途
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use
WO2026027659A1 (en) 2024-07-31 2026-02-05 Seni-Preps B.V. Improved immunoglobulin single variable domains that inhibit urease and use thereof

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5238919A (en) * 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
ES2073394T3 (es) 1987-06-10 1995-08-16 Dana Farber Cancer Inst Inc Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JPH06508371A (ja) 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE348175T1 (de) 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc Method eder intrazellularen bindung von zielgerichteten molekülen
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
SG55079A1 (en) 1992-12-11 1998-12-21 Dow Chemical Co Multivalent single chain antibodies
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
GB9311454D0 (en) 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
JPH08511160A (ja) 1993-06-09 1996-11-26 ユニリーバー・ナームローゼ・ベンノートシャープ 形質転換真カビによってＳｃＦｖフラグメントを含んでなる融合タンパク質を生産する方法
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
DK0795608T3 (da) * 1994-11-30 2003-07-21 Ajinomoto Kk Antitrombotisk middel og monoklonale anti-von Willebrandfaktor antistoffer
AU4964896A (en) 1995-01-19 1996-08-07 Research Foundation Of The State University Of New York, The Genes encoding an insect calcium channel
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
DE69604298T2 (de) 1995-09-22 2000-05-18 Bioimage A/S, Soeborg Varianten des grünen fluoreszenzproteins, gfp
US6239259B1 (en) 1996-04-04 2001-05-29 Unilever Patent Holdings B.V. Multivalent and multispecific antigen-binding protein
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
AU9262598A (en) 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US5895466A (en) 1997-08-19 1999-04-20 At&T Corp Automated natural language understanding customer service system
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
AU3295299A (en) 1998-02-19 1999-09-06 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
ATE535154T1 (de) * 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
ATE232298T1 (de) 1998-07-06 2003-02-15 Euroscreen Sa Bioluminenztest für agonisten oder antagonisten eines kalzium-gekuppelten-rezeptors
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
CA2344606A1 (en) * 1998-10-23 2000-05-04 Huabing Yuan Conformation-specific anti-von willebrand factor antibodies
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
WO2000055318A2 (en) 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
ID30380A (id) 1999-04-22 2001-11-29 Unilever Nv Penghambatan infeksi virus menggunakan protein pengikat antigen bervalensi tunggal
ATE422545T1 (de) 1999-06-18 2009-02-15 Cv Therapeutics Inc Regulierung mittels atp binding cassette transporter proteins abc1
ES2358576T3 (es) 1999-07-05 2011-05-11 K.U. LEUVEN RESEARCH & DEVELOPMENT Detección de la actividad del factor de von-willebrand (vwf).
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
DK1233987T3 (da) 1999-11-29 2009-09-28 Bac Ip B V Immobiliserede enkelt-domæne antigenbindende molekyler
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US20040053340A1 (en) 2000-12-13 2004-03-18 De Haard Johannes Joseph Protein arrays
GB0031448D0 (en) 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
DE10105526B4 (de) 2001-02-07 2004-12-23 Robert Bosch Gmbh Verfahren zur Herstellung einer Klappenanordnung
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US20050136056A1 (en) * 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
AU2003251238A1 (en) * 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004041862A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
RU2357974C2 (ru) * 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
SI1639011T1 (sl) * 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
AU2005293752A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
PL1836500T3 (pl) * 2005-01-14 2010-12-31 Ablynx Nv Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
WO2008049881A2 (en) 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
EP2252303A2 (en) 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor

Also Published As

Publication number Publication date
LTPA2019504I1 (lt) 2020-07-27
BE2019C503I2 (enExample) 2025-12-10
ES2694247T3 (es) 2018-12-19
BRPI0609797B8 (pt) 2021-05-25
CN101213214B (zh) 2014-06-25
BRPI0609797A2 (pt) 2010-04-27
LT2444424T (lt) 2018-10-25
CA2608873A1 (en) 2006-11-23
JP2008539775A (ja) 2008-11-20
RU2433139C2 (ru) 2011-11-10
NL300966I1 (nl) 2019-02-13
BRPI0609797B1 (pt) 2018-07-03
NO20076475L (no) 2008-02-18
PT3415535T (pt) 2021-02-02
PL2444424T3 (pl) 2019-01-31
PL3415535T3 (pl) 2021-06-14
HUE039846T2 (hu) 2019-02-28
CY2019006I2 (el) 2020-05-29
EP2007814A2 (en) 2008-12-31
HUS1900005I1 (hu) 2019-03-28
AU2006249090A8 (en) 2006-11-23
US20100022452A1 (en) 2010-01-28
US20130136736A1 (en) 2013-05-30
EP3415535B1 (en) 2020-12-09
WO2006122825A2 (en) 2006-11-23
WO2006122825A9 (en) 2007-03-29
LUC00099I1 (enExample) 2019-02-12
NO20190279A1 (no) 2007-12-17
ZA200709570B (en) 2008-10-29
NZ563392A (en) 2009-12-24
EP3243839A1 (en) 2017-11-15
AU2006249090B2 (en) 2012-08-23
LTC2444424I2 (lt) 2020-07-27
ES2852423T3 (es) 2021-09-13
US20100330084A1 (en) 2010-12-30
NO2021020I1 (no) 2021-05-20
WO2006122825A3 (en) 2007-10-04
IL187168A0 (en) 2008-02-09
EP2444424B1 (en) 2018-08-08
MX2007014564A (es) 2008-02-07
FR19C1005I1 (fr) 2019-03-22
AU2006249090A1 (en) 2006-11-23
TR201815552T4 (tr) 2018-11-21
PT2444424T (pt) 2018-11-09
EP3415535A1 (en) 2018-12-19
IL187168A (en) 2015-05-31
RU2007147381A (ru) 2009-06-27
JP4986997B2 (ja) 2012-07-25
NO345342B1 (no) 2020-12-21
CA2960105A1 (en) 2006-11-23
KR101414438B1 (ko) 2014-07-10
US8372398B2 (en) 2013-02-12
DK2444424T3 (en) 2018-12-03
CY1122579T1 (el) 2020-05-29
LUC00099I2 (enExample) 2019-12-27
IL208607A0 (en) 2010-12-30
KR20080023301A (ko) 2008-03-13
EP2444424A1 (en) 2012-04-25
SI2444424T1 (sl) 2018-10-30
NL300966I2 (nl) 2019-04-11
CN101213214A (zh) 2008-07-02
CA2608873C (en) 2017-04-25
CY2019006I1 (el) 2020-05-29
US7807162B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
EP2056848A4 (en) USE OF EXTRACTS FOR THE TREATMENT OF VIRAL DISEASES
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP1881823A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF EYE DISEASES
EP1781303A4 (en) METHOD AND REAGENTS FOR THE TREATMENT OF METABOLISM DISEASES
EP1644039A4 (en) COMPOSITIONS AND METHOD FOR TREATING COOLING DISORDER
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
EP1838320A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS
EP1601251A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
EP2063889A4 (en) SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1816913A4 (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND ILLNESS IN CONNECTION WITH THE ANGIOGENIC FUNCTION
EP2268647A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP2091955A4 (en) ALKOXY COMPOUNDS FOR THE TREATMENT OF DISEASES
EP1850880A4 (en) APTAMERIC THERAPEUTICS FOR THE TREATMENT OF COMPLEMENTARY SERIOUS DISEASES
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
EP2120930A4 (en) USE OF CHROMIHISTIDINATE FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
EP1931691A4 (en) ODKASE INHIBITORS FOR THE TREATMENT OF MALARIA
EP2307011A4 (en) USE OF ISOINDOLENE FOR THE TREATMENT OF NEURO BEHAVIORAL DISORDERS
EP2328584A4 (en) TREATMENT OF NEUROLOGICAL DISEASES WITH HUPERZIN
EP2311472A4 (en) MEANS TO REDUCE COGNITIVE INTERFERENCE
EP2077838A4 (en) METHOD FOR TREATING RELATED DISEASES AND COMPOSITIONS THEREFOR
EP1933813A4 (en) SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER
EP1750513A4 (en) USE OF GPCR54 LIGANDS FOR THE TREATMENT OF BARRENESS
EP2219447A4 (en) S-ALKYLISOTHIOURONIUM DERIVATIVES FOR THE TREATMENT OF UTERUS HYPERCONTACTILITY DISORDERS